Koller William C, Tse Winona
Department of Neurology, Mt. Sinai School of Medicine, New York, NY 10029, USA.
Neurology. 2004 Jan 13;62(1 Suppl 1):S1-8. doi: 10.1212/wnl.62.1_suppl_1.s1.
Levodopa, introduced in the late 1960s, was the first highly effective drug for the symptomatic treatment of Parkinson's disease (PD) and remains the mainstay of pharmacologic treatment. However, long-term treatment has important limitations. The disease continues to progress despite treatment with levodopa, and a neuroprotective therapy is urgently required. In addition, motor complications associated with chronic levodopa therapy are an important source of disability. Treatment of these complications forms a major focus of modern PD management, and it is in this area that recent advances in our knowledge offer the best opportunity for therapeutic gain. In the search for improved therapies, suitable outcome measures to better assess overall disability in PD and disease progression are essential.
左旋多巴于20世纪60年代末问世，是首个用于帕金森病（PD）症状性治疗的高效药物，至今仍是药物治疗的主要手段。然而，长期治疗存在重要局限性。尽管使用左旋多巴进行治疗，疾病仍在进展，因此迫切需要一种神经保护疗法。此外，与慢性左旋多巴治疗相关的运动并发症是致残的重要原因。这些并发症的治疗是现代帕金森病管理的主要重点，正是在这一领域，我们知识的最新进展为治疗获益提供了最佳机会。在寻求改进疗法的过程中，合适的结局指标对于更好地评估帕金森病的整体残疾程度和疾病进展至关重要。
